MannKind Corp. (MNKD)

[JC4033]

$7.50 to $7.70 coming quicker than later surrounding much anticipated launch of Afreeza. While the float remains at 30%, shorts are ignoring the fact MNKD is much closer to launch for the first time after several years and attempts to get approval from the FDA. The recent Forbes article does not necessarily say anything new, but the article clearly distinguishes Afreeza from Exubera. Add another fact and without any disrespect, Al Mann was somewhat of a concern for past and present investors who were thinking change was overdue. The coming launch and with Al's step down should enlighten investors change of mind because all things are new. I consider myself as a savvy investor and one must adapt to the change and sentiment of a stock. I say to you investors/longs/shorts/day traders/swing traders/scalpers, think today where Mannkind is now, and that now has nothing to do with past failed attempts for approval. The only technicality which should not be taken out of the equation is this has always spiked big when in catalyst mode.